KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Net Cash Flow (2016 - 2025)

Boston Scientific (BSX) has disclosed Net Cash Flow for 17 consecutive years, with $668.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 132.84% to $668.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 442.24% year-over-year, with the annual reading at $1.5 billion for FY2025, 442.24% up from the prior year.
  • Net Cash Flow hit $668.0 million in Q4 2025 for Boston Scientific, down from $737.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q1 2024 to a low of -$2.0 billion in Q4 2024.
  • Historically, Net Cash Flow has averaged $7.0 million across 5 years, with a median of $27.5 million in 2021.
  • Biggest five-year swings in Net Cash Flow: surged 6844.44% in 2022 and later plummeted 2411.11% in 2024.
  • Year by year, Net Cash Flow stood at $9.0 million in 2021, then soared by 6844.44% to $625.0 million in 2022, then plummeted by 112.96% to -$81.0 million in 2023, then tumbled by 2411.11% to -$2.0 billion in 2024, then skyrocketed by 132.84% to $668.0 million in 2025.
  • Business Quant data shows Net Cash Flow for BSX at $668.0 million in Q4 2025, $737.0 million in Q3 2025, and -$180.0 million in Q2 2025.